### Guardant Health Asia, Middle East & Africa (AMEA)

Genomic testing can help advanced stage cancer patients find treatment options. At Guardant Health AMEA, we are committed to providing a high-quality and accessible test option to patients in Asia, Middle East and Africa.

We work with leading health service providers to help give you and your doctors the comprehensive genomic profiling information you need. For questions about how to access Guardant360<sup>®</sup>, please contact our local partner.

If you have any queries, send us an email at: clientservices@guardantamea.com.



### How Do You Order Guardant360<sup>®</sup>?



Ask your physician about placing an order for the Guardant360<sup>®</sup> kit.

### 2.

Two tubes of blood (10ml each) will be drawn.

3.





The blood specimens will be sent to Guardant Health's laboratory in the US.

#### 4.

Upon receipt in the US laboratory, the test report will be ready in approximately seven days.

5.





The test report will be sent to your physician.

#### 6.

Your physician can use the information to select the most appropriate treatment.



## Guardant360<sup>®</sup> Sample Test Result

(For illustrative purposes only)

ngaran tean Trait Hasan Unix Nooget Utarc Gancoloso Opec Spectrum Septus	rut, co co 43 rute da 2010 date to data date date ficial ficial	Northeast March Sentill Accessed: Probability in the Constrainty Accessed: The March Senter, Senter March March Senter, State Senter, Senter Proc. 1981, 111 - 1115 (Senter Senter) Accessed Recognition, January Report	4
			Complete Formal Personnel May in page 4

Alteration	%-ofDFLA-or Ampirtuation	Associated RDA apparent throughts	Official trial anoiability program in	
50/19 LB(64	8.5%	C Districti, Gefferdi, Aberrik	190	
S(PR Arginianai	later (1)	C Nacharana	Ves	
TPSO R 158P	12%	Nove	Yes	

Inequelo el Unicertitato Digenintancio-

an Lang (Ling) In terminal interaction and the second devices at a second finitum of despite typing the atomic is as well.

Grangerend Allocations

INCOMPANY.	train start and	-	to share the to	in comme	tend of coding	de la las is	theorem by	taxes then	obcorrented	the is in particular

We evaluated 74 genes, including the following guideline-recommended genes for NSCLC:							
FQ-0 11801 (11894	ALS	P051	9944	AND	ERBET (HERC)	1987	]



Helping advanced cancer patients get the right treatment with a simple blood draw





scan for more info



# **Patient Brochure**

### What is Guardant360®?

The Guardant360<sup>®</sup> assay is Guardant Health's breakthrough liquid biopsy for cancer patients with advanced solid tumors. This test is done using circulating tumor DNA (ctDNA), which is produced when tumors shed small pieces of their genetic material into the bloodstream. Traces of this ctDNA can be detected in the blood using our digital sequencing technology.

Over 70 clinically-relevant genes are examined in the Guardant360<sup>®</sup> test to identify genomic alterations within your cancer's DNA. This helps your physician understand which alterations exist in your cancer without the complications and delays of a tissue biopsy. As a result, physicians are able to see the most current genomic profile of your tumor and recommend appropriate treatment.

### Why choose Guardant360®?

#### Simple and Safe

- Requires only two tubes of blood for testing (10ml each)
- Non-invasive liquid biopsy for advanced solid tumors
- Avoid the complications and delays of invasive tissue biopsies
- A safer alternative to repeat tissue biopsies

#### REFERENCE: 1. Leighl NB et al. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer, Clin Cancer Res. 2019



#### **Quick and Accurate**

- Turnaround time of approximately seven days for the blood test results upon receipt in the US laboratory, making quick treatment decisions a reality
- 90% agreement with tissue<sup>1</sup> for targetable alterations, making this a feasible alternative to pick up actionable tumor mutations missed during tissue biopsies
- Detects all four classes of genomic variations in 70+ genes most relevant to solid tumors and microsatellite instability-high (MSI-high)
- Comprehensive testing for targeted therapy options

#### **Used by Leading Oncologists**

validated by over

peer-reviewed

publications

100

ordered by over 6,000 oncologists worldwide backed by over **100,000** clinical samples



Is Guardant360<sup>®</sup> right for you?

### YES, if you are an:

 Advanced stage cancer patient with a solid tumor, whose tissue biopsy is insufficient for genetic testing

 Advanced stage cancer patient who wants to identify targeted therapy options while avoiding an invasive repeat tissue biopsy



Early stage cancer
A cancer that is stable or responding to therapy
Blood cancer / hematologic malignancy